Mitapivat, a novel medicinal agent, represents a promising development in the management of erythroid disorders such as pyruvate kinase deficiency (PKD). This unique drug functions as a potent PKR, boosting its activity and, consequently, enhancing erythropoiesis. Its function is believed to rectify metabolic abnormalities seen in these inherited c